-
1
-
-
1442355578
-
HIV drug resistance
-
Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
-
(2004)
N Engl J Med
, vol.350
, pp. 1023-1035
-
-
Clavel, F.1
Hance, A.J.2
-
2
-
-
7244234570
-
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe
-
Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 9 (2004) 695-702
-
(2004)
Antivir Ther
, vol.9
, pp. 695-702
-
-
Pillay, D.1
-
3
-
-
3142660152
-
The prevalence of antiretroviral drug resistance in the United States
-
Richman D.D., Morton S.C., Wrin T.F., Hellman N., Berry S., Shapiro S.F., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
-
(2004)
AIDS
, vol.18
, pp. 1393-1401
-
-
Richman, D.D.1
Morton, S.C.2
Wrin, T.F.3
Hellman, N.4
Berry, S.5
Shapiro, S.F.6
-
4
-
-
0037043652
-
Antiretroviral drug-resistance among patients recently infected with HIV
-
Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral drug-resistance among patients recently infected with HIV. N Engl J Med 347 (2002) 385-394
-
(2002)
N Engl J Med
, vol.347
, pp. 385-394
-
-
Little, S.J.1
Holte, S.2
Routy, J.P.3
Daar, E.S.4
Markowitz, M.5
Collier, A.C.6
-
5
-
-
33846025131
-
Epidemiology of antiretroviral drug resistance in drug-naïve persons
-
Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr Opin Infect Dis 20 (2007) 22-32
-
(2007)
Curr Opin Infect Dis
, vol.20
, pp. 22-32
-
-
Geretti, A.M.1
-
6
-
-
41449090659
-
SPREAD programme: transmission of drug-resistant HIV-1 in Europe remains limited to single classes
-
Wensing A.M.J., Vercauteren J., van de Vijver D.A., Albert J., Asjo B., Balotta C., et al. SPREAD programme: transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22 (2008) 625-635
-
(2008)
AIDS
, vol.22
, pp. 625-635
-
-
Wensing, A.M.J.1
Vercauteren, J.2
van de Vijver, D.A.3
Albert, J.4
Asjo, B.5
Balotta, C.6
-
7
-
-
42149172733
-
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database
-
McColl D.J., Chappey C., Parkin N.T., and Miller M.D. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther 13 (2008) 189-197
-
(2008)
Antivir Ther
, vol.13
, pp. 189-197
-
-
McColl, D.J.1
Chappey, C.2
Parkin, N.T.3
Miller, M.D.4
-
8
-
-
33646769915
-
Interpreting resistance data for HIV-1 therapy management-know the limitations
-
Van Laethem K., and Vandamme A.M. Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev 8 (2006) 37-43
-
(2006)
AIDS Rev
, vol.8
, pp. 37-43
-
-
Van Laethem, K.1
Vandamme, A.M.2
-
9
-
-
0344474694
-
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
-
Hertogs K., de Béthune M.-P., Miller V., Ivens T., Schel P., Van Cauwenberge A., et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 (1998) 269-276
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 269-276
-
-
Hertogs, K.1
de Béthune, M.-P.2
Miller, V.3
Ivens, T.4
Schel, P.5
Van Cauwenberge, A.6
-
10
-
-
0034019566
-
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
-
Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44 (2000) 920-928
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 920-928
-
-
Petropoulos, C.J.1
Parkin, N.T.2
Limoli, K.L.3
Lie, Y.S.4
Wrin, T.5
Huang, W.6
-
11
-
-
34547841291
-
Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling
-
Vermeiren H., Van Craenenbroeck E., Alen P., Bacheler L., Picchio G., Lecocq P., et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145 (2007) 47-55
-
(2007)
J Virol Methods
, vol.145
, pp. 47-55
-
-
Vermeiren, H.1
Van Craenenbroeck, E.2
Alen, P.3
Bacheler, L.4
Picchio, G.5
Lecocq, P.6
-
12
-
-
42649118796
-
Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
-
Winters B.W., Montaner J., Harrigan P.R., Gazzard B., Pozniak A., Miller M.D., et al. Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 48 (2007) 26-34
-
(2007)
J Acquir Immune Defic Syndr
, vol.48
, pp. 26-34
-
-
Winters, B.W.1
Montaner, J.2
Harrigan, P.R.3
Gazzard, B.4
Pozniak, A.5
Miller, M.D.6
-
13
-
-
33845943963
-
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
-
Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21 (2007) 215-223
-
(2007)
AIDS
, vol.21
, pp. 215-223
-
-
Shafer, R.W.1
Rhee, S.Y.2
Pillay, D.3
Miller, V.4
Sandstrom, P.5
Schapiro, J.M.6
-
14
-
-
60449096553
-
-
Los Alamos National Laboratory Database, Los Alamos, NM, USA
-
Los Alamos National Laboratory Database, Los Alamos, NM, USA. www.hiv.lanl.gov.
-
-
-
-
15
-
-
84887667223
-
-
The French ANRS National Agency for AIDS Research
-
The French ANRS (National Agency for AIDS Research): HIV French Resistance http://www.hivfrenchresistance.org/2008/tab1.html.
-
Resistance
-
-
French, H.I.V.1
-
16
-
-
60449090686
-
-
Stanford University HIV Drug Resistance Database
-
Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu/index.html.
-
-
-
-
17
-
-
60449095062
-
-
US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council OARAC, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 2008. AIDS info web site
-
US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 2008. AIDS info web site: http://AIDSinfo.nih.gov.
-
-
-
-
18
-
-
60449100323
-
-
Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2, December 2007 at the EACS web site: http://www.eacs.eu/guide/index.htm.
-
Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2, December 2007 at the EACS web site: http://www.eacs.eu/guide/index.htm.
-
-
-
-
19
-
-
41349117196
-
Efficacy and safety of once-daily regimens in the treatment of HIV infection
-
Molina J.-M. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 68 (2008) 567-578
-
(2008)
Drugs
, vol.68
, pp. 567-578
-
-
Molina, J.-M.1
-
20
-
-
14744283486
-
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
-
Mo H., King M.S., King K., Molla A., Brun S., and Kempf D. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 79 (2005) 3329-3338
-
(2005)
J Virol
, vol.79
, pp. 3329-3338
-
-
Mo, H.1
King, M.S.2
King, K.3
Molla, A.4
Brun, S.5
Kempf, D.6
-
21
-
-
0038369071
-
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
-
Ait-Khaled M., Rakik A., Griffin P., Stone C., Richards N., Thomas D., Falloon J., and Tisdale M. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther 8 (2003) 111-120
-
(2003)
Antivir Ther
, vol.8
, pp. 111-120
-
-
Ait-Khaled, M.1
Rakik, A.2
Griffin, P.3
Stone, C.4
Richards, N.5
Thomas, D.6
Falloon, J.7
Tisdale, M.8
-
22
-
-
2442657656
-
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens
-
Colonno R., Rose R., Mclaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189 (2004) 1802-1810
-
(2004)
J Infect Dis
, vol.189
, pp. 1802-1810
-
-
Colonno, R.1
Rose, R.2
Mclaren, C.3
Thiry, A.4
Parkin, N.5
Friborg, J.6
|